Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health
Primary Purpose
Iron Deficiency, Iron Deficiency Anemia
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Ferrous Sulfate + folic acid
Folic acid
Sponsored by
About this trial
This is an interventional prevention trial for Iron Deficiency focused on measuring iron deficiency, iron deficiency anemia, infant, pregnancy
Eligibility Criteria
Inclusion Criteria:
- uncomplicated singleton pregnancy, first enrollment visit ≤ 20 weeks gestation -
Exclusion Criteria:
- < 18 years of age
- did not live in the county
- did not anticipate delivery at participating hospital
- were not mentally competent
- had a chronic health problem or hemoglobin < 100 g/L at the initial visit
- were taking iron at the time.
Sites / Locations
- Peking University First Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Folic acid
Ferrous Sulfate + folic acid
Arm Description
Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
Outcomes
Primary Outcome Measures
Maternal iron status at follow-up prenatal visit
Maternal iron status at follow-up prenatal visit
Secondary Outcome Measures
Cord-blood iron status
Infant gestational age
Infant birth weight
Full Information
NCT ID
NCT02221752
First Posted
August 18, 2014
Last Updated
August 19, 2014
Sponsor
Zhao gengli
Collaborators
Vifor Pharma
1. Study Identification
Unique Protocol Identification Number
NCT02221752
Brief Title
Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health
Official Title
Impact of Iron/Folic Acid Versus Folic Acid Supplements During Pregnancy on Maternal and Children's Health: A Randomized Controlled Trial in China
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
June 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
December 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Zhao gengli
Collaborators
Vifor Pharma
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
According to a national study in 2002, the prevalence of ID, IDA, and ID+IDA among pregnant women in China was 42.6%, 9.1%, and 61.7% respectively. A similar study in Hebei province at the same time showed that the prevalence of IDA among pregnant and lactating mothers was 46.39% and 47.21% respectively. There was a significant difference between urban and rural areas. Women living in rural areas had higher chances of having IDA (p<0.01). WHO and UNICEF recommend taking iron, folic acid and multiple micronutrients during pregnancy. However, we don't know much about their influence on maternal and infant health and their clinical effectiveness. Health Department of China recommends taking 400ug folic acid before pregnancy and during early pregnancy. But for various reasons, not all expecting mothers take this advice. Besides, we don't have a national level technical standard of how to take nutrition supplements during pregnancy. Therefore, it's crucial for us to study if iron/folic acid or folic acid only can prevent perinatal complications, as well as their influences on infant and toddler health.
The purpose of this study is to test whether taking iron/folic acid and folic acid only from early pregnancy until delivery will lower the chances of pregnancy complications, and to see how supplements affect gestation results. As well, it will evaluate a) whether taking iron supplement during pregnancy can prevent IDA during pregnancy; b) whether taking iron supplement can increase mother and fetus iron storage; and c) how mother's iron level affects newborn's iron level. We hope to understand nutrition conditions during pregnancy and investigate the relations between pregnancy diet and complications during pregnancy, weight gain during pregnancy, and newborn birth weight. We will evaluate the influence of taking iron and folic acid during pregnancy on the health of infants and toddlers.
Detailed Description
Iron deficiency (ID) is the world's most common single nutrient disorder, differentially affecting pregnant women and infants everywhere. The study was conducted in China, a rapidly developing country where ID often occurs among pregnant women and infants in the absence of generalized undernutrition. The study was a collaboration between Peking University First Hospital and three local hospitals (Sanhe Maternity and Child Health Care Center [MCHC], Sanhe General County Hospital, and Sanhe Hospital of Traditional Chinese Medicine). Eligible pregnant women were enrolled from June 2009 through December 2011 and randomized in a 1:1 ratio to receive iron and folic acid or folic acid only. The study protocol was approved by the institutional review board of Peking University First Hospital, Beijing, China. Women were recruited (n=2367) at their first prenatal visit at Sanhe MCHC. Those with uncomplicated singleton pregnancies and first prenatal visits ≤ 20 weeks gestation were invited to participate. Women were randomized and received 2 supplements: iron/placebo and folic acid. Project personnel instructed the participants to take two capsules per day (one of each kind of supplement) from enrollment to delivery. Participants received a 3-month supply of each supplement upon enrollment and at the second study visit (26-30 weeks). The number of doses received and consumed or missed was recorded by project personnel. The primary outcomes were maternal iron status at follow-up visits (26-30 weeks and 36-40 weeks), cord-blood iron status, and infant gestational age and birth weight. Data analysis compares pregnancy iron level between two study groups and how it relates to pregnancy outcomes, including pregnancy and delivery complications, preterm rate, perinatal death rate, and birth rate. Data analysis also includes evaluating pregnancy nutrition conditions and analyzing associations with weight changes during pregnancy, and rates of pregnancy diabetes, pregnancy high blood pressure, fetus growth restriction, low birth weight, and fetal macrosomia. Up to 75% of pregnant women worldwide are anemic, with about half due to ID. The public health implications of study findings could be profound.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Iron Deficiency, Iron Deficiency Anemia
Keywords
iron deficiency, iron deficiency anemia, infant, pregnancy
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2367 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Folic acid
Arm Type
Experimental
Arm Description
Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
Arm Title
Ferrous Sulfate + folic acid
Arm Type
Experimental
Arm Description
Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
Intervention Type
Dietary Supplement
Intervention Name(s)
Ferrous Sulfate + folic acid
Intervention Description
Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
Intervention Type
Dietary Supplement
Intervention Name(s)
Folic acid
Intervention Description
Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
Primary Outcome Measure Information:
Title
Maternal iron status at follow-up prenatal visit
Time Frame
26-30 weeks
Title
Maternal iron status at follow-up prenatal visit
Time Frame
36-40 weeks
Secondary Outcome Measure Information:
Title
Cord-blood iron status
Time Frame
delivery
Title
Infant gestational age
Time Frame
delivery
Title
Infant birth weight
Time Frame
delivery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
uncomplicated singleton pregnancy, first enrollment visit ≤ 20 weeks gestation -
Exclusion Criteria:
< 18 years of age
did not live in the county
did not anticipate delivery at participating hospital
were not mentally competent
had a chronic health problem or hemoglobin < 100 g/L at the initial visit
were taking iron at the time.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhao Gengli, MD
Organizational Affiliation
Peking University First Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University First Hospital
City
Beijing
ZIP/Postal Code
100034
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
26063068
Citation
Zhao G, Xu G, Zhou M, Jiang Y, Richards B, Clark KM, Kaciroti N, Georgieff MK, Zhang Z, Tardif T, Li M, Lozoff B. Prenatal Iron Supplementation Reduces Maternal Anemia, Iron Deficiency, and Iron Deficiency Anemia in a Randomized Clinical Trial in Rural China, but Iron Deficiency Remains Widespread in Mothers and Neonates. J Nutr. 2015 Aug;145(8):1916-23. doi: 10.3945/jn.114.208678. Epub 2015 Jun 10.
Results Reference
derived
Learn more about this trial
Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health
We'll reach out to this number within 24 hrs